argenx SE(ARGX)

Description: argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company’s lead clinical stage product candidates include ARGX-113, a product in Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis and immune thrombocytopenia; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of hematological cancers, such as T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome. It is also developing ARGX-111 to treat solid tumors with MET amplification; ARGX-109 for the treatment of rheumatoid arthritis; ARGX-112 to treat skin inflammation; ARGX-115, a cancer immunotherapy-focused product candidate; and ARGX-116 for the treatment of dyslipidemia. The company has license and collaboration agreements with AbbVie S.Á.R.L.; Bird Rock Bio, Inc.; LEO Pharma A/S; Shire International GmbH; and Bayer AG. argenx SE was founded in 2008 and is based in Breda, the Netherlands.

---

Keywords: Cancer Biopharmaceutical Solid Tumors Immunotherapy Autoimmune Disease Inflammation Cancer Immunotherapy Rheumatoid Arthritis Lymphoma Acute Myeloid Leukemia Lipid Myelodysplastic Syndrome Treatment Of Autoimmune Disease Myasthenia Gravis Dyslipidemia Hematological Cancers Immune Thrombocytopenia Thrombocytopenia Janus Kinase Inhibitor Myasthenia Treatment Of Hematological Cancers Skin Inflammation T Cell Lymphoma Therapies For The Treatment Of Autoimmune Diseases Rgx

---

Home Page: www.argenx.com

ARGX Technical Analysis

Willemstraat 5
Breda, 4811 AH
Netherlands
Phone: 31 10 703 8441

---

Officers

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)